Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri

KURT ÖMÜRLÜ, İMRAN; Karaman, Göksun; USLU, Meltem; Sendur, Neslihan; BOZKURT ŞAVK, EKİN; BÜYÜKÖZTÜRK KARUL, ASLIHAN; Gokbulut, Cengiz; KOZACI, Leyla Didem

Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri

Meltem USLU, (Boş)

Neslihan ŞENDUR, (Boş)

EKİN BOZKURT ŞAVK, (Boş)

ASLIHAN BÜYÜKÖZTÜRK KARUL, (*Biyokimya Anabilim Dalı, Aydın, Türkiye)

Leyla Didem KOZACI, (*Biyokimya Anabilim Dalı, Aydın, Türkiye)

Cengiz GÖKBULUT, (Adnan Menderes Üniversitesi Veteriner Fakültesi, Farmakoloji Toksikoloji Anabilim Dalı, Aydın, Türkiye)

Göksun KARAMAN, (Boş)

İmran Kurt ÖMÜRLÜ (Adnan Menderes Üniversitesi Tıp Fakültesi, Biyoistatistik ve Tıbbi Bilişim Anabilim Dalı, Aydın, Türkiye)

Türkderm-Deri Hastalıkları ve Frengi Arşivi

2 0

Yıl: 2017 Cilt: 51 Sayı: 3 Sayfa Aralığı: 92 - 97 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri

Öz:

Amaç: Homosistein kardiyovasküler hastalık, otoimmünite-enflamasyon ve DNA metilasyonu ile ilişkilendirilen sülfür içeren bir aminoasittir. Bu olgu-kontrol çalışmasında psoriazisli hastalarda plazma homosistein düzeylerinin ve homosisteini etkileyen folik asit, vitamin B6 ve vitamin B12 düzeylerinin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Polikliniğimizde takip edilen erişkin plak tip psoriazis hastaları ile yaş ve cinsiyet uyumlu kontrol grubunda alkol, kahve ve sigara tüketimi sorgulandı, katılımcıların boy ve ağırlıkları ölçüldü. Hastaların Psoriazis Alan Şiddet İndeksleri (PAŞİ) hesaplandı. Sabah açlık kan örnekleri alınarak homosistein, folik asit, vitamin B12, vitamin B6, kan şekeri, serum total kolesterol, trigliserid, yüksek yoğunluklu lipoproteinler (HDL), eritrosit sedimantasyon hızı (ESH) ve C-reaktif protein (CRP) değerleri çalışıldı.Bulgular: Psoriazisli hasta (n=43) ve kontrol grubu (n=47) arasında vücut kitle indeksi, alkol tüketimi ve kahve tüketimi açısından anlamlı farklılık yoktu. Medyan PAŞİ 10,0 (8,3-12,8) idi. Sigara kullanan kişi oranı psoriazisli hastalarda anlamlı yüksekti. Psoriazisli hastalar ile kontrol gurubu arasında plazma homosistein, folik asit, vitamin B12, vitamin B6, total kolesterol, trigliserid, ESH ve CRP değerleri açısından anlamlı farklılık olmadığı görüldü. HDL-kolesterol düzeyi hasta grubunda daha düşüktü (p=0,001). Serum homosistein düzeyi erkeklerde kadınlara göre daha yüksek saptandı (p=0,014). Serum homosistein düzeyi ile katılımcıların yaşı, PAŞİ, ESH, CRP ve lipid değerleri arasında herhangi bir ilişki saptanmadı. Homosistein düzeyi ile folik asit ve vitamin B12 arasında ters ilişki vardı (sırasıyla p=0,000, r=-0,436, p=0,047, r=-0,204). Homosistein ile vitamin B6 arasında ilişki saptanmadı. Sonuç: İzlemimizdeki psoriazis hastalarında plazma homosistein yüksekliği görülmemiştir. Enflamatuvar hastalıklarda yüksek düzeyde saptanan ve yüksekliği kardiyovasküler hastalık risk belirteci kabul edilen homosistein, bu hasta popülasyonunda genetik ve/veya beslenmeyle ilişkili özelliklerden dolayı dengede tutulmuş olabilir.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Beslenme ve Diyetetik Endokrinoloji ve Metabolizma

Blood homocysteine, folic acid, vitamin B12 and vitamin B6 levels in psoriasis patients

Öz:

Background and Design: Homocysteine, a sulfur-containing amino acid, is known to be related with autoimmunity-inflammation, cardiovascular disease and DNA methylation. In this case-control study, we aimed to determine plasma homocysteine, folic acid, vitamin B12 and vitamin B6 levels in patients with psoriasis.Materials and Methods: Smoking, alcohol and coffee consumption habits were recorded in adult patients with plaque-type psoriasis and age- and sex-matched controls. Height and weight measurements were performed and Psoriasis Area and Severity Index (PASI) scores were calculated. Fasting venous blood samples were collected to determine homocysteine, folic acid, vitamin B12, vitamin B6, glucose, total cholesterol, triglyceride, high density lipoprotein (HDL), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels.Results: There was no significant difference between psoriasis patients (n=43) and controls (n=47) in body mass index and alcohol and coffee consumption. Smoking rate was significantly high in psoriasis patients. The median PASI score was 10.0 (8.3-12.8). Plasma homocysteine, folic acid, vitamin B12, vitamin B6, total cholesterol, triglyseride, ESR and CRP values were not significantly different between patients and the controls. HDL level was low in psoriasis patients (p=0.001). Plasma homocysteine level was higher in males than in females. There was no relationship of homocysteine levels with patient's age, PASI scores, ESR, CRP values and lipids. Homocysteine levels were inversely related with folic acid and vitamin B12 (p=0.000, r=-0.436, p=0.047, r=-0.204, respectively). We did not find any relationship between homocysteine and vitamin B6 levels.Conclusion: There was no increase in plasma homocysteine levels in psoriasis patients we followed up. Homocysteine level increases in inflammatory disorders and this increase is accepted as a cardiovascular disease marker. Homocysteine homeostasis may be balanced in our patients because of the genetic background and/or nutritional habits in this population.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Beslenme ve Diyetetik Endokrinoloji ve Metabolizma

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Gelfand JM, Neiman AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
2. Mallbris L, Akre O, Granath F, et al: Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225- 30.
3. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH: Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and metaanalysis. J Invest Dermatol 2013;133:2340-6.
4. Ryan C, Kirby B: Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015;33:41-55.
5. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE: Heart disease in psoriasis. J Am Acad Dermatol 2007;57:347-54.
6. Ray JG: Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101-6.
7. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S: Homocyst(e)ine and cardiovascular disease: a critical review of epidemiologic evidence. Ann Intern Med 1999;131:363-75.
8. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Wollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
9. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. JAMA 1997;277:1775-81.
10. Boushey CJ, Beresford SA, Omenn GS. Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
11. Ganguly P, Alam SF: Role of homocysteine in the development of cardiovascular disease. Nutrition J 2015;14:6.
12. Nygard O, Vollset SE, Refsum H, Brattsröm L, Ueland PM: Total homocysteine and cardiovascular disease. J Intern Med 1999;246:425-54.
13. Akcali C, Buyukcelik B, Kirtak N, Inaloz S: Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis. J Int Med Res 2014;42:386-94.
14. Erturan I, Köroğlu BK, Adiloğlu A, et al: Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study. Int J Dermatol 2014;53:503-9.
15. Liew SC, Das-Gupta E, Wong SF, Lee N, Safdar N, Jamil A: Association of methylenetetrahydrofolate reductase (MTHFR) 677 C > T gene polymorhism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a casecontrol study. Nutr J 2012;11:1.
16. Romani J, Caixas A, Carrascosa JM, Ribera M, Rigla M, Luelmo J: Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol 2012;166:1237-44.
17. Ataseven A, Kesli R, Kurtipek GS, Ozturk P: Assesment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis factor receptor-1, interleukin-6, homocysteine and uric acid levels in patients with psoriasis. Dis Markers 2014;2014:541709.
18. Cakmak SK, Gül U, Kiliç C, Gönül M, Soylu S, Kiliç A: Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol 2009;23:300-3.
19. Bilgiç R, Yıldız H, Karabudak Abuaf Ö, İpçioğlu OM, Doğan B: Psoriasis hastalarında serum asimetrik dimetilarjinin düzeylerinin değerlendirilmesi. Turkderm 2015;49:13-8.
20. Karabacak E, Aydin E, Ozcan O et al: Methylentetrahydrofolate reductase (MTHFR) 677 C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis. Int J Clin Exp Med 2014;7:697-702.
21. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y: Inflammation and hypercoagulable state in adult psoriatic men. Acta Dermato Venereol 2008;88:337-40.
22. Vanizor Kural B, Orem A, Cimşit G, Uydu HA, Yandi YE, Alver A: Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003;332:23-30.
23. Didar Balcı D, Yönden Z, Doğramacı ÇA, Duran N: Hafif ve orta şiddetli psoriyazis hastalarında serum yüksek sensitif C reaktif protein ve homosistein düzeyleri. Turkderm 2009;43:53-7.
24. Bilgiç Ö, Altınyazar HC, Baran H, Ünlü A: Serum homocysteine, asymmetric dimethyl arginine (ADMA) and other arginine-NO pathway metabolite levels in patients with psoriasis. Arch Dermatol Res 2015;307:439-44.
25. Giannoni M, Consales V, Campanati A, et al: Homocysteine plasma levels in psoriasis patients: Our experience and review of the literature. J Eur Acad Dermatol Venereol 2015;29:1781-5.
26. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G: Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155:1165-9.
27. Brazzelli V, Grasso V, Fornara L, et al: Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. Int J Immunopathol Pharmacol 2010;23:911-6.
28. Richetta AG, Mattozzi C, Macaluso L, et al: Homocysteine plasmatic status in patients with psoriasis. Eur J Dermatol 2011;21:621-3.
29. Gisondi P, Malerba M, Malara G, et al: C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol 2010;23:1195-202.
30. Tobin AM, Hughes R, Hand EB, Leong T, Graham IM, Kirby B: Homocysteine status and cardiovascular risk factors in patients with psoriasis: a casecontrol study. Clin Exp Dermatol 2011;36:19-23.
31. Refsum H, Helland S, Ueland PM: Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving lowdose methotrexate treatment. Clin Pharmacol Ther 1989;46:510-20.
32. Mandaviya PR, Stolk L, Heil SG: Homocysteine and DNA methylation: a review of animal and human literature. Mol Genet Metab 2014;113:243-52.
33. Chandra A, Ray A, Senapati S, Chatterjee R: Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol 2015;64:313-23.
34. Baiqiu W, Songbin F, Guiyin Z, Pu L: Study of the relationship between psoriasis and the polymorphic site C677T of methylenetetrahydrofolate reductase. Chin Med Sci J 2000;15:119-20.
35. Zhou S, Zhang Z, Xu G: Notable epigenetic role of hyperhomocysteinemia in atherosclerosis. Lipids Health Dis 2014;13:134.
36. Asefi M, Vaisi-Raygani A, Khodarahmi R, et al: Methylentetrahydrofolatereductase (rs1801133) polymorphism and psoriasis: contribution to oxidative stress, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report. J Eur Acad Dermatol Venereol 2014;28:1192-8.
37. Baiqiu W, Songbin F, Guiyin Z, Pu L: Study of the relationship between psoriasis and the polymorphic site C677T of methylenetetrahydrofolate reductase. Chin Med Sci J 2000;15:119-20.
38. Krajcovicová-Kudlácková M, Blazícek P, Kopcová J, Béderová A, Babinská K: Homocysteine levels in vegetarians versus omnivores. Ann Nutr Metab 2000;44:135-8.
39. Kang SS, Wong PW, Malinow MR: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-98.
40. Lazzerini PE, Capecchi PL, Selvi E, et al: Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007;6:503-9.
41. Dawson H, Collins G, Pyle R, Deep-Dixit V, Taub DD: The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev 2004;125:107-10.
42. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D: Homocysteine accumulates in supernatants od stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003;134:53-6.
43. Scarpa R, Manguso F, D'Arienzo A, et al: Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241-6.
44. Schatteman L, Mielants H, Veys EM, et al: Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995;22:680-3. 45. https://www.bda.uk.com/foodfacts/FolicAcid.pdf
46. Liew SC, Gupta ED: Methylenetetrahydrofolat reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and associated diseases. Eur J Med Genet 2015;58:1-10.
47. Karabacak E, Aydın E, Ozcan O, et al: Methylentetrahydrofolate reductase (MTHFR) 677 C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis. Int J Clin Exp Med 2014;7:697-702.
48. Izmirli M, Sen BB, Rifaioglu E, et al: Methylenetetrahydrofolate reductase (MTHFR) C6777T polymorphism in psoriasis in southern Turkey. An Bras Dermatol 2016;91:611-3.
49. Liew SC, Das-Gupta E, Wong SF, Lee N, Safdar N, Jamil A: Association of methylenetetrahydrofolate reductase (MTHFR) 677 C > T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a casecontrol study. Nutrition J 2012;11:1
50. Vasku V, Bienertova-Vasku J, Necas M, Vasku A: MTHFR (methylenetetrahydrofolate reductase) C677T polymorphism and psoriasis. Clin Exp Med 2009;9:327-31.
51. Weger W, Hofer A, Stanger O, et al: The methylenetetrahydrofolate reductase 677C>T gene polymorphism is not associated with chronic plaque psoriasis. Exp Dermatol 2008;17:748-51.
52. Wu D, Shi D, Yang L, Zhu X: Association between methylenetetrahydrofolate reductase C677T polymorphism and psoriasis: A meta analysis. J Dermatol 2016;43:162-9.
53. Qi JH, Qi JH, Shi N, Chen YJ, Nie G: Association between MTHFR 677C/T polymorphism and psoriasis risk: a meta analysis. Genet Mol Res 2015;14:3869-76.

APA	USLU M, Sendur N, BOZKURT ŞAVK E, BÜYÜKÖZTÜRK KARUL A, KOZACI L, Gokbulut C, Karaman G, KURT ÖMÜRLÜ İ (2017). Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. , 92 - 97.
Chicago	USLU Meltem,Sendur Neslihan,BOZKURT ŞAVK EKİN,BÜYÜKÖZTÜRK KARUL ASLIHAN,KOZACI Leyla Didem,Gokbulut Cengiz,Karaman Göksun,KURT ÖMÜRLÜ İMRAN Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. (2017): 92 - 97.
MLA	USLU Meltem,Sendur Neslihan,BOZKURT ŞAVK EKİN,BÜYÜKÖZTÜRK KARUL ASLIHAN,KOZACI Leyla Didem,Gokbulut Cengiz,Karaman Göksun,KURT ÖMÜRLÜ İMRAN Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. , 2017, ss.92 - 97.
AMA	USLU M,Sendur N,BOZKURT ŞAVK E,BÜYÜKÖZTÜRK KARUL A,KOZACI L,Gokbulut C,Karaman G,KURT ÖMÜRLÜ İ Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. . 2017; 92 - 97.
Vancouver	USLU M,Sendur N,BOZKURT ŞAVK E,BÜYÜKÖZTÜRK KARUL A,KOZACI L,Gokbulut C,Karaman G,KURT ÖMÜRLÜ İ Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. . 2017; 92 - 97.
IEEE	USLU M,Sendur N,BOZKURT ŞAVK E,BÜYÜKÖZTÜRK KARUL A,KOZACI L,Gokbulut C,Karaman G,KURT ÖMÜRLÜ İ "Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri." , ss.92 - 97, 2017.
ISNAD	USLU, Meltem vd. "Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri". (2017), 92-97.

APA	USLU M, Sendur N, BOZKURT ŞAVK E, BÜYÜKÖZTÜRK KARUL A, KOZACI L, Gokbulut C, Karaman G, KURT ÖMÜRLÜ İ (2017). Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. Türkderm-Deri Hastalıkları ve Frengi Arşivi, 51(3), 92 - 97.
Chicago	USLU Meltem,Sendur Neslihan,BOZKURT ŞAVK EKİN,BÜYÜKÖZTÜRK KARUL ASLIHAN,KOZACI Leyla Didem,Gokbulut Cengiz,Karaman Göksun,KURT ÖMÜRLÜ İMRAN Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. Türkderm-Deri Hastalıkları ve Frengi Arşivi 51, no.3 (2017): 92 - 97.
MLA	USLU Meltem,Sendur Neslihan,BOZKURT ŞAVK EKİN,BÜYÜKÖZTÜRK KARUL ASLIHAN,KOZACI Leyla Didem,Gokbulut Cengiz,Karaman Göksun,KURT ÖMÜRLÜ İMRAN Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. Türkderm-Deri Hastalıkları ve Frengi Arşivi, vol.51, no.3, 2017, ss.92 - 97.
AMA	USLU M,Sendur N,BOZKURT ŞAVK E,BÜYÜKÖZTÜRK KARUL A,KOZACI L,Gokbulut C,Karaman G,KURT ÖMÜRLÜ İ Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. Türkderm-Deri Hastalıkları ve Frengi Arşivi. 2017; 51(3): 92 - 97.
Vancouver	USLU M,Sendur N,BOZKURT ŞAVK E,BÜYÜKÖZTÜRK KARUL A,KOZACI L,Gokbulut C,Karaman G,KURT ÖMÜRLÜ İ Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri. Türkderm-Deri Hastalıkları ve Frengi Arşivi. 2017; 51(3): 92 - 97.
IEEE	USLU M,Sendur N,BOZKURT ŞAVK E,BÜYÜKÖZTÜRK KARUL A,KOZACI L,Gokbulut C,Karaman G,KURT ÖMÜRLÜ İ "Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri." Türkderm-Deri Hastalıkları ve Frengi Arşivi, 51, ss.92 - 97, 2017.
ISNAD	USLU, Meltem vd. "Psoriazis hastalarında kan homosistein, folik asit, vitamin B12 ve vitamin B6 düzeyleri". Türkderm-Deri Hastalıkları ve Frengi Arşivi 51/3 (2017), 92-97.